Clinical Trials Browser

Phase 1/2 × OTHER × Non Small Cell Lung Cancer NSCLC × Clear all

NCT07087223 2025-07-25

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Phase 1/2 Recruiting

Non Small Cell Lung Cancer NSCLC